Jennifer L. Malin, MD, PhD

Targeting chemotherapy with 70-gene MammaPrint signature in patients 60 years or younger with node-negative breast cancer is likely to be cost-effective.

We linked health insurance records to cancer registry data to analyze colony-stimulating factor use, finding wide divergence from that recommended by practice guidelines.

We present findings about the prevalence and predictors of financial incentives for quality reported by oncologists and surgeons in Los Angeles County, California.